636-patient angiogenesis review finds no cancer signal as Isomab prepares ISM-001 for first human study
Isomab’s review of 11 historical therapeutic-angiogenesis studies found similar malignancy rates with pro-angiogenic treatment and placebo, supporting the safety rationale for preclinical ISM-001 without proving the new antibody is safe.